Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Trial ID or NCT#
NCT03510208
Status
RECRUITING
Purpose
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Official Title
Phase I/II, Open-Label Study Evaluating the Efficacy and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures
Investigator(s)
Gordon Li, MD
Neurosurgeon
Professor of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences and of Otolaryngology - Head & Neck Surgery (OHNS)
Reena Thomas, MD PhD
Neuro-oncologist
Clinical Professor, Adult Neurology
Clinical Professor (By courtesy), Neurosurgery
Melanie Hayden Gephart
Neurosurgeon
Professor of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences
Steven D. Chang, MD
Neurosurgeon,
Aneurysm neurosurgeon,
Cerebrovascular neurosurgeon,
Pituitary tumors neurosurgeon,
Stereotactic neurosurgeon
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology and Neurological Sciences
Chirag Patel, MD, PhD
Lindsay Scott Moore
Otology and neurotology specialist
Assistant Professor of Otolaryngology - Head & Neck Surgery
Contact us to find out if this trial is right for you.
Contact
Sandra Torres
650-723-5281
View on ClinicalTrials.gov
